Study of IRX4204 for Treatment of Early Parkinson's Disease
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This is a single site, open-label study designed to examine dopamine transporter density
using [123I]β-CIT SPECT imaging before and following treatment with IRX4204 for a 30-day
period in early Parkinson's disease patients. In addition, clinical evaluations will be
performed to evaluate the effect of IRX4204 treatment on the motor and cognitive symptoms of
PD.